Comparison of Two Bronchodilator Inhalers in Adolescents and Adults With Exercise-Induced Asthma

Exercise-induced Bronchospasm Clinical Trial

Official title:

A Single-Dose Efficacy Comparison of Albuterol Hydrofluoroalkane (HFA) Breath-operated Inhaler (BOI) (Volare Easi-Breathe™) and Albuterol HFA Meter Dose Inhaler (MDI) (Volare™) in Adolescents and Adults With Exercise-Induced Bronchospasm

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00085774
• Other study ID #: IXR-302-4-167
• Status: Completed
• Phase: Phase 3
• Start date: June 30, 2004
• Est. completion date: September 30, 2004

Study information

• Verified date: November 2021
• Source: Teva Branded Pharmaceutical Products R&D, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study was designed to examine the effectiveness of two bronchodilator inhalers in patients who have exercise-induced asthma.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: September 30, 2004
• Est. primary completion date: September 30, 2004
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years to 40 Years

Eligibility

Inclusion Criteria:

• Provide written informed consent
• Male or non-pregnant, non-nursing females aged 12 40 years, inclusive, at the first screening visit
• Have exercise-induced bronchospasm (EIB), with or without asthma, as demonstrated by a =15% decrease in pre-challenge absolute FEV1 observed up to 60 minutes following an exercise challenge conducted at the first screening visit
• Predicted FEV1 =70% for age, height, gender, and, where applicable, race following an 8 hour period without [beta]2 agonist use
• Have no contraindications for exercising maximally
• Ability to perform spirometry reproducibly (i.e., the difference between the two highest FEV1 values out of a minimum of three and a maximum of eight values obtained at the first screening visit must not exceed 0.2 L)
• Ability to self-perform PEF (peak expiratory flow) determinations with a handheld peak flow meter
• Can tolerate withdrawal of applicable medications for qualification at both screening visits
• Normal chest X ray, or, if abnormal, is consistent with asthma and shows no evidence of other active disease
• Otherwise healthy individuals with clinically acceptable medical history, physical examination, vital signs, and 12 lead ECG (electrocardiogram; with 30 second Lead II rhythm strip)
• Body mass index (BMI) of 19 29 kg/m2 (BMI = weight [kg] / height2 [m])
• Non-smokers for at least one year prior to the first screening visit and have maximum smoking histories of ten-pack years (i.e., equivalent to 20 cigarettes per day for 10 years).

Exclusion Criteria:

• Allergy or sensitivity to albuterol or to other components of the formulations used in the drug
• Exposure to investigational drugs within 30 days prior to the first screening visit
• Require continuous treatment with [beta] blockers (administered by any route), MAO (monoamine oxidase) inhibitors, tricyclic antidepressants, cromones (by any route), antileukotrienes, and/or systemic corticosteroids
• Treated with oral or injectable corticosteroids within the 12 weeks prior to the first screening visit
• The prescribed dose regimen of any required inhaled corticosteroids has not been stable for at least four weeks prior to the first screening visit NOTE: Patients requiring subsequent dosage adjustment of these drug products must be discontinued from the study.
• Inability to tolerate or unwillingness to comply with required washout periods for all applicable medications and xanthine-containing foods and beverages prior to the screening visit
• Treatment in an emergency room for asthmatic symptoms or hospitalization for asthmatic symptoms within twelve months prior to the first screening visit
• Experienced an upper respiratory tract infection and/or sinusitis associated with exacerbation of asthmatic symptoms not requiring emergency room treatment and/or hospitalization and/or treatment with oral or injected corticosteroids that has not resolved within four weeks prior to the screening visit
• History and/or presence of any clinically-significant acute or chronic disease, including but not limited to bronchitis, emphysema, active tuberculosis, bronchiectasis, cystic fibrosis, clinically significant cardiovascular disease (including cardiac arrhythmias and uncontrolled hypertension), clinically significant hepatic, renal, or endocrine dysfunction, stroke, uncontrolled diabetes, hyperthyroidism, convulsive disorders, and neoplastic disease other than basal cell carcinoma of the skin
• Known or suspected substance abuse (e.g., alcohol, marijuana, etc.) and/or presence of any other medical or psychological conditions that in the investigator's opinion should preclude study enrollment.
• Are employees of this study site or have a family member associated with the conduct of this study at this site
• Previous enrollment in an IVAX Research-sponsored Albuterol HFA aerosol asthma study.

Related Conditions & MeSH terms

• Asthma, Exercise-Induced
• Bronchial Spasm
• Exercise-induced Bronchospasm

Intervention

Drug:
• albuterol aerosol by HFA MDI
albuterol HFA MDI 160 mcg
• albuterol aerosol by HFA BOI
albuterol HFA BOI 160 mcg
• placebo aerosol by HFA
placebo HFA

Locations

Country	Name	City	State
United States	Colorado Allergy and Asthma Centers, PC	Denver	Colorado
United States	Colorado Allergy and Asthma Centers, PC	Englewood	Colorado
United States	Colorado Allergy and Asthma Centers, PC	Lakewood	Colorado

Sponsors (1)

Lead Sponsor	Collaborator
Teva Branded Pharmaceutical Products R&D, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The primary endpoint was mean maximum % change in the baseline absolute forced expiratory volume in 1 second (FEV1) value observed up to 1 hour post-challenge.		Three doses 2-7 days apart
Secondary	Mean maximum percent change in the baseline percent predicted FEV1 value observed up to one hour post-challenge		exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes
Secondary	Mean maximum absolute change in the baseline absolute FEV1 value observed up to one hour post-challenge		exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes
Secondary	Mean percent change in the baseline absolute FEV1 value at each post-challenge time point		exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes
Secondary	Mean absolute change in the baseline absolute FEV1 value at each post-challenge time point		exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes
Secondary	Mean percent change in the baseline percent-predicted FEV1 value at each post-challenge time point		exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes
Secondary	Mean largest negative (or mean smallest positive) percent change in the baseline absolute FEV1 value observed up to one hour post-challenge		exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes
Secondary	Mean largest negative (or mean smallest positive) percent change in the average test-day pre-dose baseline percent predicted FEV1 value observed up to one hour post-challenge		exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes
Secondary	Time to recovery (in minutes) measured from time of completion of exercise challenge to time FEV1 returns to 10% or less of baseline value during the recovery phase		exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes
Secondary	Total changes in FEV1 expressed as the baseline-adjusted area-under-the-effect curve of the percent-predicted FEV1 versus time over 60 minutes (AUEC0 60)		exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes
Secondary	Percentage of patients who are "protected" (maximum percent decrease in the baseline absolute FEV1 <10%), "partially protected" (10 20%), and "unprotected" (>20%).		exercise challenge 30 minutes after dosing and assessments over 60 +/- 10 minutes